Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Inclusion Criteria:

• Aged 18 years on the day of inclusion (US) and aged 21 years on the day of inclusion (Puerto Rico)
• A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

        Is of non-childbearing potential. To be considered of non-childbearing potential, a female
        must be postmenopausal for at least 1 year, or surgically sterile OR Is of childbearing
        potential and agrees to use an effective contraceptive method or abstinence from at least 4
        weeks prior to study intervention administration until at least 12 weeks after study
        intervention administration.
        Exclusion Criteria:
          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
             within the preceding 6 months; or long-term systemic corticosteroid therapy
             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
          -  Previous history of myocarditis, pericarditis, and / or myopericarditis
          -  Self-reported thrombocytopenia, contraindicating IM vaccination based on
             Investigator's judgment
          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,
             contraindicating IM vaccination based on Investigator's judgment
          -  Moderate or severe acute illness / infection (according to Investigator's judgment) or
             febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of vaccination. A
             prospective participant should not be included in the study until the condition has
             resolved or the febrile event has subsided
          -  Self-reported or documented seropositivity for human immunodeficiency virus, hepatitis
             B virus, or hepatitis C virus NOTE: The above information is not intended to contain
             all considerations relevant to a patient's potential participation in a clinical
             trial.